株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血液疾患向け薬剤および診断:世界市場

Drugs and Diagnostics for Hematological Disorders: Global Markets

発行 BCC Research 商品コード 263924
出版日 ページ情報 英文 504 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
血液疾患向け薬剤および診断:世界市場 Drugs and Diagnostics for Hematological Disorders: Global Markets
出版日: 2016年09月20日 ページ情報: 英文 504 Pages
概要

当レポートでは、世界の血液疾患向け治療薬および診断市場について調査し、市場の概要、世界市場の動向分析とCAGR予測、血液疾患・血液癌・血液診断別の市場分析、さまざまな白血病とその治療法のレビュー、FDA認可薬の説明、および主要企業のプロファイルなどをまとめ、お届けします。

第1章 イントロダクション

第2章 サマリー

第3章 血液疾患

  • 血液
  • 血液疾患
    • 貧血
    • 巨赤芽球性貧血
    • ヘモグロビン異常
    • 溶血性貧血
    • 原発性血小板血症
    • 出血性疾患
    • 栓友病
    • 血栓症
    • 深部静脈血栓症
    • 遺伝性出血性毛細管拡張症
    • 赤血球増加症
    • 白血球疾患
    • 好中球減少症、ほか

第4章 血液癌

  • 典型的な分類
    • 急性骨髄性白血病
    • 慢性骨髄性白血病
    • 急性リンパ性白血病
    • 慢性リンパ球性白血病
    • ホジキンリンパ腫
    • 非ホジキンリンパ腫
    • 多発性骨髄腫
    • 骨髄異形成症候群

第5章 白血病

  • リンパ性白血病
  • 骨髄性白血病
    • 症状
    • 病因
    • 診断
    • 検査
    • 治療
  • T細胞前リンパ球性白血病
  • 若年性骨髄単球性白血病
  • 白血病の病期
  • 治療・薬剤
    • 幹細胞移植
    • 化学療法
  • 結論

第6章 リンパ腫

  • 概要
    • リンパ腫の病因
    • 分類
    • 病期
  • 非ホジキンリンパ腫
    • 兆候・症状
    • 診断・検査
    • 予後因子
  • リンパ腫の治療
    • 放射線・化学療法
    • 放射線療法
    • 化学療法
    • 生物学的療法
    • 補完/代替療法

第7章 骨髄腫

  • 概要
    • 病因
    • 症状
    • 合併症
    • 種類
    • 発生
    • 診断
    • 検査
    • 病期
    • 治療・予後
    • その他の薬物療法
    • 新薬治療
  • 結論

第8章 骨髄異形成症候群

  • 分類
  • 国際予後スコアリングシステム
  • 診断・検査
  • 予後・治療選択肢
    • 化学療法
    • 対症療法
  • 薬剤プロファイル
  • 結論

第9章 骨髄増殖性疾患

  • 慢性骨髄増殖性疾患の種類
  • 分類:WHO
  • 慢性骨髄増殖性疾患の病期
  • 真性赤血球増加症
  • 慢性特発性骨髄線維症
  • 本態性血小板血症
  • 慢性好中球性白血病
  • 慢性好酸球性白血病
  • サマリー

第10章 血液癌の疫学

  • インド
  • ケニア
  • 世界の血液癌発症率
  • 米国における血液癌発症率
  • 血液癌による死者
  • 白血病
  • リンパ腫
  • 骨髄腫
  • 骨髄異形成症候群
  • 血液疾患・発生率
  • 出血性障害

第11章 血液用器具類・試薬:世界市場の見通し

  • 血液系悪性腫瘍
  • 市場ダイナミクス
  • 世界市場

第12章 血液疾患治療市場

  • 治療薬市場
  • 主要企業
  • 貧血治療市場
  • 血栓症治療市場
  • 血小板凝集阻害薬・市場への影響
  • 好中球減少症治療市場
  • 血友病
  • 結論

第13章 血液癌治療市場

  • 概要
  • 血液癌治療薬市場
    • 悪性血液疾患の分類
    • 世界の細胞毒性治療市場
  • 白血病市場・課題
    • 慢性骨髄性白血病市場
    • 急性リンパ性白血病市場
    • 急性骨髄性白血病市場
    • 慢性リンパ球性白血病市場
    • リンパ腫治療薬市場
    • 多発性骨髄腫治療市場
    • 骨髄異形成症候群市場
    • 本態性血小板血症市場
    • 骨髄線維症市場

第14章 特許情勢・現在の発展動向

  • 血液癌治療薬:特許失効
  • 新規承認
  • 新しい血液癌治療薬

第15章 主要企業のプロファイル

第16章 参考資料

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM116B

REPORT HIGHLIGHTS

The global market for hematology drugs and diagnostics is expected to grow from nearly $86.5 billion in 2015 to $124.3 billion in 2020 at a compound annual growth rate of 7.5% from 2015-2020.

This report provides:

  • An overview of the global market for drugs and diagnostics for hematological disorders.
  • Analyses of global market trends, with data from2015, and projections of CAGRs through 2020.
  • A breakdown of the market by hematological diseases, hematological cancers, and hematological diagnostics.
  • A review of blood cancers, such as various types of leukemia, lymphoma, and myeloma, and their therapies.
  • Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
  • Delineation of drugs approved by the FDA for hematological disorders.
  • Profiles of key companies in the industry.

SCOPE OF THE STUDY

The scope of this study covers instruments, reagents, testing, screening technology and the therapeutics markets for hematological disorders, including hemophilia and blood cancers. The report also discusses the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends, and clinical and new developments.

ANALYST'S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • ABOUT BCC RESEARCH
  • CONDITIONS OF PURCHASE
  • ADDITIONAL COPIES
  • CUSTOM ANALYSES
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, 2012-2020 ($ MILLIONS)

CHAPTER 3 - HEMATALOGICAL DISORDERS

  • TABLE 1: KEY BLOOD DISORDERS
  • TABLE 2: MALIGNANT BLOOD DISORDERS
  • TABLE 3: NONMALIGNANT BLOOD DISORDERS
  • BLOOD
    • TABLE 4: TYPE OF BLOOD CELLS AND FUNCTIONS
    • TABLE 5: COMPONENTS OF BLOOD
  • BLOOD DISORDERS/DISEASES
    • ANEMIA
      • Types of Anemia
        • TABLE 6: THREE MAJOR TYPES OF ANEMIA
        • TABLE 7: CAUSES OF ANEMIA
      • Symptoms
        • TABLE 8: SYMPTOMS OF ANEMIA
        • TABLE 9: ANEMIA: TYPES, CAUSES AND TREATMENT
    • MEGALOBLASTIC ANEMIAS
      • Cobalamin Deficiency
        • TABLE 10: DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY BY CLASS
      • Folate Deficiency
        • TABLE 11: DRUGS THAT CAN CAUSE FOLATE DEFICIENCY
      • Diagnostic Tests
        • Schilling Test
        • Serum Ferritin and Iron Studies
        • Other Tests
      • Treatment
    • HEMOGLOBIN DISORDERS
      • Categories
        • Thalassemia
        • Sickle Cell Anemia
          • TABLE 12: SICKLE CELL ANEMIA: KEY FACTS
      • Causes
      • World Health Organization's Resolutions
    • HEMOLYTIC ANEMIA
      • TABLE 13: LAB TESTS FOR ANEMIA
      • Treatment
        • Anemia Medications
    • PRIMARY THROMBOCYTHEMIA
      • Hemostasis: Steps of Mechanism
        • TABLE 14: HEMOSTASIS: THREE MAJOR STEPS
      • Types of Hemostasis
      • Hemostasis in Emergency Medicine
      • Artificial Hemostasis
        • TABLE 15: DRUGS THAT AFFECT THE ACTIVITY OF PLATELETS
        • TABLE 16: ANTICOAGULANTS THAT ACT ON THROMBIN
    • BLEEDING DISORDERS
      • TABLE 17: BLEEDING DISORDERS
      • TABLE 18: SYMPTOMS OF BLEEDING DISORDERS
      • TABLE 19: SIGNS AND TESTS FOR BLEEDING DISORDERS
      • Hemophilia
        • TABLE 20: KEY CHARACTERISTICS OF HEMOPHILIA
        • Classification
        • Historical Background
        • The Clotting Cascade
        • Hemorrhage
        • Natural Inhibitors
        • Acquired Hemophilia
        • Hemophilia Types
        • Symptoms and Complications
        • Diagnosis
        • Hemophilia and Bleeding
        • Genetic Testing
        • Treatment
          • TABLE 21: FVIII INHIBITORS
          • TABLE 22: MEDICATIONS FOR TREATING HEMOPHILIA
      • Factor VIII Products
        • TABLE 23: FACTOR VIII PRODUCTS
      • Antifibrinolytics
        • TABLE 24: ANTIFIBRINOLYTICS BY DRUG
      • Antihemophilic Agents
        • TABLE 25: ANTIHEMOPHILIC AGENTS BY CLASS
      • Coagulation Factor VIIa, Recombinants
        • Factor VIIa, Recombinant (NovoSeven)
        • Monoclonal Antibodies
          • Rituximab (Rituxan)
      • von Willebrand Disease
        • Symptoms and Diagnosis
        • Treatment
    • THROMBOPHILIA
      • Diagnosis and Treatment
    • THROMBOSIS
      • TABLE 26: FORMATION OF THROMBUS
      • Superficial Thrombophlebitis
    • DEEP VENOUS THROMBOSIS
      • Tests
      • Treatment
      • Surgery
    • HEREDITARY HEMORRHAGIC TELANGIECTASIA
    • ERYTHROCYTOSIS
      • Absolute Polycythemia
        • Types
          • Primary Polycythemia
          • Secondary Polycythemia
      • Chuvash Polycythemia
      • Relative Polycythemia
    • WHITE BLOOD CELL DISORDERS
      • Treatment
    • NEUTROPENIA
      • Causes
        • TABLE 27: CAUSES OF NEUTROPENIA
      • Symptoms and Diagnosis
      • Treatment
    • NEUTROPHILIA
    • BLOOD DISORDERS AFFECTING PLATELETS
      • TABLE 28: WHITE BLOOD CELL DISORDERS
      • Thrombocytopenia
        • Treatment
      • Lymphocytopenia
        • Treatment
      • Lymphocytic Leukocytosis
      • Monocytosis
      • Thrombocythemia and Thrombocytosis
        • Types
          • Primary Thrombocythemia
        • Secondary Thrombocytosis
          • TABLE 29: CAUSES OF SECONDARY THROMBOCYTOSIS
        • Symptoms
          • TABLE 30: DIAGNOSTIC TESTS FOR THROMBOCYTHEMIA
        • Treatment
          • TABLE 31: MEDICINES FOR THROMBOCYTHEMIA
        • Thrombocytopenia
          • Causes
            • TABLE 32: CAUSES OF THROMBOCYTOPENIA
    • RARE CONDITIONS THAT CAUSE BLOOD CLOTS
      • Signs and Symptoms
        • TABLE 33: SIGNS OF EXTERNAL BLEEDING
        • Tests
        • Treatment
    • SEVERE THROMBOCYTOPENIA
    • EOSINOPHILS AND DISORDERS
      • TABLE 34: COMMON DRUGS TO TREAT EOSINOPHILIA
    • BASOPHILIC DISORDERS
    • PLASMA CELL DISORDERS

CHAPTER 4 - HEMATOLOGICAL CANCERS

  • TABLE 35: HEMATOLOGICAL CANCERS (BLOOD CANCERS)
  • CLASSIC CLASSIFICATION
    • TABLE 36: RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE U.S., 2016 (NUMBER/%)
    • TABLE 37: TYPES OF HEMATOLOGICAL CANCERS
    • ACUTE MYELOID LEUKEMIA
    • CHRONIC MYELOID LEUKEMIA
    • ACUTE LYMPHOCYTIC LEUKEMIA
    • CHRONIC LYMPHOCYTIC LEUKEMIA
    • HODGKIN LYMPHOMA
    • NON-HODGKIN LYMPHOMA
      • Treatment and Side Effects
    • MULTIPLE MYELOMA
    • MYELODYSPLASTIC SYNDROME
      • Diagnosis
        • TABLE 38: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2014-2016
        • TABLE 39: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2012
        • TABLE 40: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2011
        • TABLE 41: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 1996-2010

CHAPTER 5 - LEUKEMIA

  • LYMPHOCYTIC LEUKEMIAS
  • MYELOGENOUS LEUKEMIAS
    • TABLE 42: TYPES OF LEUKEMIA
    • TABLE 43: TYPES OF LEUKEMIA AND KEY FEATURES
    • SYMPTOMS
    • CAUSES
    • DIAGNOSIS
    • TESTS
      • TABLE 44: DIAGNOSTIC EXAMS FOR LEUKEMIA
      • Complete Blood Count
      • White Cell Differential
      • Blood Smear
        • TABLE 45: ADDITIONAL TESTS
      • Fluorescence In Situ Hybridization (FISH)
      • Flow Cytometry
      • Immunophenotyping
      • Karyotype Test
      • Polymerase Chain Reaction
      • Bone Marrow Aspiration/Biopsy
      • Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
      • Immunophenotyping or Phenotyping by Flow Cytometry
      • Cytogenetics and Fluorescent In Situ Hybridization
      • Polymerase Chain Reaction (PCR)
        • TABLE 46: PCR TESTS
      • Non-Laboratory Tests
        • TABLE 47: NON-LABORATORY TESTS
    • TREATMENT
      • TABLE 48: COMMON TREATMENTS USED TO FIGHT LEUKEMIA
      • TABLE 49: NEWER CLASSES OF DRUGS
      • Drug Therapies for Blood Cancers
        • TABLE 50: ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT
        • TABLE 51: DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
        • TABLE 52: DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA
        • TABLE 53: DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA
        • TABLE 54: DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA
      • Hairy Cell Leukemia: Treatment
    • T-CELL PROLYMPHOCYTIC LEUKEMIA
      • TABLE 55: T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN
    • JUVENILE MYELOMONOCYTIC LEUKEMIA
    • STAGES OF LEUKEMIA
      • TABLE 56: FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS
    • TREATMENTS AND DRUGS
      • Stem Cell Transplantation
        • Allogeneic Stem Cell Transplant
        • Autologous Stem Cell Transplant
      • Chemotherapy
        • Types of Chemotherapy for Leukemia
          • Chemotherapy for Acute Leukemias
          • Chemotherapy for Chronic Leukemias
            • TABLE 57: CHEMOTHERAPY DRUGS FOR CML
            • TABLE 58: CHEMOTHERAPY DRUGS FOR CLL
          • Intrathecal Chemotherapy
        • Targeted Drug Therapy for Leukemia
          • TABLE 59: TARGETED THERAPY DRUGS
        • Monoclonal Antibody Therapy
        • Radioimmunotherapy
          • TABLE 60: ADVANTAGES OF RADIOIMMUNOTHERAPY
        • Radiation Therapy
          • TABLE 61: COMMON RADIATION TREATMENTS: LEUKEMIA
        • External Beam Radiation Therapy
        • Total Body Irradiation
        • Total Marrow Irradiation
        • Nutrition Therapy after a Stem Cell Transplant
        • Managing Side Effects with Naturopathic Therapies
        • Pain Management for Leukemia
          • TABLE 62: PAIN MEDICATIONS
          • TABLE 63: EMERGING THERAPIES FOR LEUKEMIA
    • CONCLUSIONS

CHAPTER 6 - LYMPHOMA

  • OVERVIEW
    • LYMPHOMA CAUSES
      • TABLE 64: CAUSES OF LYMPHOMA
    • CLASSIFICATION
      • TABLE 65: LYMPHOMA TYPES
    • STAGING
      • TABLE 66: STAGING FOR HL AND NHL TUMORS
    • NON-HODGKIN LYMPHOMA
      • TABLE 67: MATURE B-CELL NEOPLASMS
      • TABLE 68: MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS
      • TABLE 69: HODGKIN LYMPHOMA
      • TABLE 70: IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS
    • SIGNS AND SYMPTOMS
      • TABLE 71: SYMPTOMS OF NON-HODGKIN LYMPHOMA
      • TABLE 72: FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS: NON HODGKIN LYMPHOMA, 2006-2012 (%)
    • DIAGNOSIS AND TESTS
      • Biopsy
      • Imaging Studies
        • TABLE 73: IMAGING TESTS FOR LYMPHOMA
      • Bone Marrow Examination
      • Other Tests
        • Lumbar Puncture
        • Organ Function Tests
    • PROGNOSTIC FACTORS
      • TABLE 74: THE INTERNATIONAL PROGNOSTIC INDEX FOR HL
      • TABLE 75: THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL
  • LYMPHOMA TREATMENT
    • RADIATION AND CHEMOTHERAPY
    • RADIATION THERAPY
    • CHEMOTHERAPY
    • BIOLOGICAL THERAPY
      • TABLE 76: PROMISING THERAPIES FOR TREATING LYMPHOMA
    • COMPLEMENTARY/ALTERNATIVE THERAPIES

CHAPTER 7 - MULTIPLE MYELOMA

  • OVERVIEW
    • CAUSE
    • SYMPTOMS
    • COMPLICATIONS OF MYELOMA
      • Cryoglobulinemia
      • Amyloidosis
    • TYPES OF MYELOMA
    • INCIDENCE
    • DIAGNOSIS
    • TESTS
      • Prognostic Indicators
        • TABLE 77: PROGNOSTIC INDICATORS FOR MYELOMA
      • Bone Marrow Examination
        • TABLE 78: OTHER BONE MARROW TESTS
    • STAGING
      • Monoclonal Gammopathy of Undetermined Significance
      • Smoldering Multiple Myeloma
      • Indolent Multiple Myeloma
      • Symptomatic Multiple Myeloma
        • TABLE 79: MYELOMA: STAGING CRITERIA
    • TREATMENT AND PROGNOSIS
      • TABLE 80: MYELOMA'S RESPONSE TO TREATMENT
      • Myeloma Therapy
      • Chemotherapy
      • Radiation Therapy
      • Stem Cell Transplantation
      • Supportive Care
        • TABLE 81: SUPPORTIVE CARE FOR MYELOMA
    • OTHER DRUG THERAPIES
    • NEW DRUG THERAPIES
      • TABLE 82: DRUGS FOR MULTIPLE MYELOMA
      • TABLE 83: NEW AND EMERGING THERAPIES FOR MYELOMA
    • CONCLUSIONS

CHAPTER 8 - MYELODYSPLASTIC SYNDROMES

  • TABLE 84: CHARACTERISTICS OF MDS
  • TABLE 85: CAUSES OF MDS
  • TABLE 86: MDS OR AML: THREE CATEGORIES
  • CLASSES OF MDS
    • TABLE 87: MYELODYSPLASTIC SYNDROMES: KEY FACTS
    • TABLE 88: FAB CLASSIFICATION OF MDS
    • TABLE 89: THE 2008 WHO CLASSIFICATION OF MDS
  • INTERNATIONAL PROGNOSTIC SCORING SYSTEM
    • TABLE 90: INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS AND PROGNOS (YEARS)
  • DIAGNOSIS AND TESTS
    • TABLE 91: CHANGES IN CELLS DUE TO MDS
  • PROGNOSIS AND TREATMENT OPTIONS
    • CHEMOTHERAPY
    • SUPPORTIVE CARE
  • DRUG PROFILES
    • EPOETIN ALFA (PROCRIT, EPOGEN)
    • DARBEPOETIN (ARANESP)
    • SARGRAMOSTIM (LEUKINE)
    • FILGRASTIM (NEUPOGEN)
    • DECITABINE (DACOGEN)
    • LENALIDOMIDE (REVLIMID)
    • VIDAZA (AZACITIDINE)
    • PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES
  • CONCLUSIONS

CHAPTER 9 - MYELOPROLIFERATIVE DISORDERS

  • TYPES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
    • TABLE 92: CHRONIC MYELOPROLIFERATIVE DISORDERS
  • CLASSIFICATION: WHO
    • TABLE 93: CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE
  • WHO CLASSIFICATION SCHEME
    • TABLE 94: MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS
  • STAGES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
  • DIAGNOSIS
    • TESTS
      • TABLE 95: DIAGNOSTIC TESTS
  • TREATMENT
    • OTHER DRUG THERAPY
  • POLYCYTHEMIA VERA
    • OVERVIEW
      • TABLE 96: SYMPTOMS OF POLYCYTHEMIA VERA
    • CAUSES
    • RISK FACTORS
      • TABLE 97: BLOOD TESTS FOR POLYCYTHEMIA VERA
    • TREATMENT OF POLYCYTHEMIA VERA
      • Drugs for Treating Polycythemia Vera
        • TABLE 98: TREATMENT FOR POLYCYTHEMIA VERA
    • PROGNOSIS
    • COMPLICATIONS
      • Blood Clots
      • Enlarged Spleen (Splenomegaly)
      • Problems Due to High Levels of Red Blood Cells
    • OTHER BLOOD DISORDERS
  • CHRONIC IDIOPATHIC MYELOFIBROSIS
    • CAUSES
      • TABLE 99: CAUSATIVE FACTORS FOR MYELOFIBROSIS
      • TABLE 100: POTENTIAL COMPLICATIONS FROM MYELOFIBROSIS
    • PATHOGENESIS
    • DIAGNOSIS
      • TABLE 101: WHO DIAGNOSTIC CRITERIA FOR PMF
    • PROGNOSIS
      • TABLE 102: RISK FACTORS
    • SYMPTOMS
      • TABLE 103: IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS
      • TABLE 104: PROGNOSIS FACTORS
    • TREATMENTS FOR MYELOFIBROSIS
      • TABLE 105: TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS
      • Experimental Drug Therapy
      • Pomalidomide
        • TABLE 106: SOMATIC MUTATIONS
    • ESSENTIAL THROMBOCYTHEMIA
      • TABLE 107: CAUSES OF THROMBOCYTOSIS
    • SYMPTOMS
      • TABLE 108: SYMPTOMS OF ESSENTIAL THROMBOCYTOSIS
    • PATHOPHYSIOLOGY
    • DIAGNOSIS
      • TABLE 109: ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA
    • TREATMENT
    • PROGNOSIS
    • CAUSES, INCIDENCE AND RISK FACTORS
    • GENES: ESSENTIAL THROMBOCYTHEMIA
    • TREATMENT OF ESSENTIAL THROMBOCYTHEMIA
      • Diagnosis
        • TABLE 110: TREATMENT OF ET
    • ANTI-PLATELET TREATMENT
    • ADP RECEPTOR ANTAGONISTS
    • PLATELET-LOWERING TREATMENT
      • Anagrelide
      • Interferon-a (IFN-a)
    • ALTERNATIVE CYTOREDUCTIVE THERAPY
      • Pipobroman (PI)
      • Busulfan (BU)
      • Prognosis
        • Implication of the Description of JAK2 V617F Mutation on the Management of ET
  • CHRONIC NEUTROPHILIC LEUKEMIA
    • TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
      • TABLE 111: TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
    • CHRONIC EOSINOPHILIC LEUKEMIA
      • TABLE 112: SYMPTOMS OF CHRONIC EOSINOPHILIC LEUKEMIA
    • TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA
      • TABLE 113: TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA
    • PIPELINE DRUGS
      • Incyte
      • Jakavi in Europe
    • SUMMARY
      • TABLE 114: CURRENT DRUGS

CHAPTER 10 - EPIDEMIOLOGY OF HEMATOLOGICAL CANCERS

  • TABLE 115: CANCER KEY FACTS
  • TABLE 116: INCREASE IN CANCER BURDEN: FACTORS
  • INDIA
  • KENYA
  • WORLDWIDE INCIDENCE OF BLOOD CANCERS
    • TABLE 117: GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO./%)
    • TABLE 118: GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO.)
    • TABLE 119: GLOBAL INCIDENCE OF BLOOD CANCERS IN MEN, 2012 (NO./%)
    • TABLE 120: GLOBAL INCIDENCE OF BLOOD CANCERS IN WOMEN, 2012 (NO./%)
    • TABLE 121: TOP 10 COUNTRIES' CANCER INCIDENCE RATES (PER 100,000 POPULATION)
  • BLOOD CANCER INCIDENCE IN THE UNITED STATES
    • TABLE 122: ESTIMATED INCIDENCE OF BLOOD CANCERS IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)
    • FIGURE 1: ESTIMATED INCIDENCE OF BLOOD CANCERS, IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)
    • TABLE 123: ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)
    • FIGURE 2: ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)
    • TABLE 124: ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
    • FIGURE 3: ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
  • DEATHS FROM BLOOD CANCERS
  • LEUKEMIA
    • NUCLEAR REACTORS AND BLOOD CANCERS
    • SIGNS AND SYMPTOMS
    • LEUKEMIA IN CHILDREN AND ADOLESCENTS
    • GLOBAL INCIDENCE
      • TABLE 125: GLOBAL INCIDENCE OF LEUKEMIA, 2012 (NUMBER/%)
    • LEUKEMIA IN THE UNITED STATES
      • TABLE 126: U.S. LEUKEMIA INCIDENCE STATISTICS, 2012
      • TABLE 127: ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)
      • FIGURE 4: ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)
      • TABLE 128: ESTIMATED NEW CASES OF LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2016
      • TABLE 129: ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)
      • FIGURE 5: ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)
      • Leukemia in Children and Adolescents
        • TABLE 130: PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)
        • FIGURE 6: PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)
      • Adolescents and Young Adults
      • Adults
        • TABLE 131: TYPES OF LEUKEMIA IN ADULTS IN THE U.S. AND AGE GROUP
        • TABLE 132: ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)
        • FIGURE 7: ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)
        • TABLE 133: AGE-ADJUSTED INCIDENCE RATES OF LEUKEMIA IN THE U.S. BY RACE, SEER 18, 2009-2013 (PER 100,000 POPULATION)
      • Survival
        • TABLE 134: FIVE-YEAR RELATIVE SURVIVAL RATES IN THE U.S. FOR LEUKEMIA, 2005-2011 (%)
        • TABLE 135: ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO).
        • FIGURE 8: ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO).
    • LEUKEMIA INCIDENCE IN THE UNITED KINGDOM
      • TABLE 136: NEW CASES OF LEUKEMIA IN THE U.K., 2013 (NO.)
      • Cause
    • WORLDWIDE MORTALITY RATES: LEUKEMIA
      • TABLE 137: GLOBAL ESTIMATES OF LEUKEMIA DEATHS/MORTALITY RATES, 2012
  • LYMPHOMA
    • SIGNS AND SYMPTOMS
    • POSSIBLE CAUSES
    • TREATMENT
    • WORLDWIDE INCIDENCE OF NHL
      • TABLE 138: GLOBAL ESTIMATED INCIDENCE RATES OF NON-HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012
      • TABLE 139: GLOBAL ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES BY ALL AGES AND BOTH SEXES, 2012
    • GLOBAL INCIDENCE OF HODGKIN'S LYMPHOMA
      • TABLE 140: GLOBAL ESTIMATED INCIDENCE OF HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012
    • CANADA: LYMPHOMA
    • EUROPEAN UNION
      • Non-Hodgkin's Lymphoma
        • TABLE 141: ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-
    • COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)
      • FIGURE 9: ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-
    • COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)
      • TABLE 142: ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-
    • COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)
      • FIGURE 10: ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-
    • COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000)
      • Hodgkin Lymphoma in EU: 2012
        • TABLE 143: ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)
        • FIGURE 11: ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)
    • LYMPHOMA IN THE UNITED STATES
      • New Cases
        • TABLE 144: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
        • FIGURE 12: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
        • TABLE 145: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)
        • FIGURE 13: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)
        • TABLE 146: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)
        • FIGURE 14: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)
        • TABLE 147: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)
        • FIGURE 15: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)
        • TABLE 148: ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)
        • FIGURE 16: ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)
        • TABLE 149: U.S. AGE-SPECIFIC NHL INCIDENCE RATES BY GENDER (ESTIMATED RATES PER 100,000 POPULATION)
        • TABLE 150: U.S. LYMPHOMA INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)
        • TABLE 151: U.S. LYMPHOMA MORTALITY RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)
      • Race and Ethnicity
      • Children
      • Adolescents and Young Adults
      • Adults
      • Survival
        • TABLE 152: STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES, BOTH SEXES BY STAGE AT DIAGNOSIS, 2002-2008 (%)
    • LYMPHOMA IN THE UNITED KINGDOM
      • TABLE 153: NEW CASES OF NON-HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)
      • TABLE 154: NON-HODGKIN LYMPHOMA DEATHS IN THE U.K. BY SEX, 2012 (NO.)
      • Hodgkin Lymphoma in the United Kingdom
        • TABLE 155: ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)
        • TABLE 156: ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)
        • FIGURE 17: ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)
  • MYELOMA
    • SYMPTOMS
    • MYELOMA INCIDENCE WORLDWIDE
      • TABLE 157: ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)
      • FIGURE 18: ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)
      • TABLE 158: ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, (PER 100,000 POPULATION)
      • FIGURE 19: ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, (PER 100,000 POPULATION)
    • MYELOMA IN EUROPEAN UNION COUNTRIES
      • TABLE 159: ESTIMATED INCIDENCE OF MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)
      • TABLE 160: DEATHS FROM MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)
    • MYELOMA IN THE UNITED STATES
      • TABLE 161: ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)
      • FIGURE 20: ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)
      • TABLE 162: ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)
      • FIGURE 21: ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)
      • TABLE 163: AGE-ADJUSTED INCIDENCE RATES OF MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)
      • TABLE 164: AGE-ADJUSTED DEATH RATES FROM MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)
      • Survival
        • TABLE 165: DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL FOR ALL AGES AND BOTH SEXES IN THE U.S. BY STAGE AT DIAGNOSIS, 2002-2008 (%)
    • MYELOMA IN THE UNITED KINGDOM
      • TABLE 166: NEW CASES OF MYELOMA IN THE U.K., 2013 (NO.)
      • TABLE 167: MYELOMA DEATHS IN THE U.K., 2012 (NO.)
    • CONCLUSIONS
  • MYELODYSPLASTIC SYNDROMES
    • SIGNS AND SYMPTOMS
      • TABLE 168: ESTIMATED NEW CASES OF MDS IN THE U.S., 2012 (NO.)
    • RACE AND ETHNICITY
  • BLOOD DISEASES AND INCIDENCE
    • ANEMIA
    • SICKLE CELL ANEMIA
    • THALASSEMIA
  • BLEEDING DISORDERS
    • HEMOPHILIA
      • Worldwide Incidence of Hemophilia
      • Mortality/Morbidity
      • Hemophilia in the United States
    • CLOTTING DISORDERS

CHAPTER 11 - HEMATOLOGY INSTRUMENTS AND REAGENTS: A GLOBAL MARKET PERSPECTIVE

  • HEMATOLOGICAL MALIGNANCIES
  • MARKET DYNAMICS: HEMATOLOGY INSTRUMENTS AND REAGENTS
    • TABLE 169: KEY FACTORS DRIVING THE GROWTH OF THE HEMATOLOGICAL DISORDERS MARKET
    • TABLE 170: GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 ($ MILLIONS)
    • FIGURE 22: GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 ($ MILLIONS)
  • GLOBAL MARKET
    • Market Drivers
      • TABLE 171: KEY HEMATOLOGY PRODUCTS
    • Key Players in Hematology Instruments
      • TABLE 172: GLOBAL MAJOR COMPANIES IN THE HEMATOLOGY MARKET
    • Key Company Profiles
      • Roche
      • Sysmex
      • Flow Cytometers
        • TABLE 173: KEY PLAYERS IN FLOW CYTOMETRY
        • TABLE 174: GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 23: GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 ($ MILLIONS)
        • TABLE 175: MAJOR FLOW CYTOMETRY APPLICATIONS
      • Coagulation Analyzers
        • TABLE 176: CELL ANALYZERS
      • Future Outlook
    • HEMATOLOGY TEST PRODUCTS AND MARKET
      • TABLE 177: HEMATOLOGY TESTS
    • COMPLETE BLOOD COUNT (CBC)
      • TABLE 178: COMPLETE BLOOD COUNT: COMPONENTS MEASURED
    • MAJOR ROUTINE AND SPECIAL HEMATOLOGY TESTS
      • Partial Thromboplastin Time
      • Total Serum Protein
      • Chemistry Panel
        • TABLE 179: TESTS INCLUDED IN A CHEMISTRY SCREEN
        • TABLE 180: CHEMISTRY SCREEN
      • Vitamin B12
      • The Cold Agglutinins Test
      • Prothrombin
      • Reticulocyte
      • Urine Cytology
        • TABLE 181: URINE TESTS AND APPLICATIONS
    • BLOOD PROTEIN TESTING
    • TUMOR MARKER TESTS
    • IN VITRO DIAGNOSTIC MARKET
      • TABLE 182: GLOBAL IVD PRODUCTS MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 24: GLOBAL IVD PRODUCTS MARKET, 2012-2020 ($ MILLIONS)
      • TABLE 183: U.S. IVD MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 25: U.S. IVD MARKET, 2012-2020 ($ MILLIONS)
      • Immunoassays
        • TABLE 184: GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, THROUGH 2020 ($ MILLIONS)
        • FIGURE 26: GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, 2012-2020 ($ MILLIONS)
      • Market Trends
        • TABLE 185: GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, THROUGH 2020 ($ MILLIONS)
        • FIGURE 27: GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, 2015-2020 ($ MILLIONS)
        • TABLE 186: KEY PLAYERS IN THE IMMUNOASSAYS MARKET
      • Molecular Diagnostics
        • TABLE 187: GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 28: GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2015-2020 ($ MILLIONS)
        • TABLE 188: MAJOR PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
    • POINT-OF-CARE MARKET
      • TABLE 189: GLOBAL POINT-OF-CARE TESTING MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 29: GLOBAL POINT-OF-CARE TESTING MARKET, 2015-2020 ($ MILLIONS)
      • TABLE 190: POC TESTING KITS
      • POC Tests
        • TABLE 191: GLOBAL MARKET FOR POC TESTS, THROUGH 2020 ($ MILLIONS)
        • FIGURE 30: GLOBAL MARKET FOR POC TESTS, 2015-2020 ($ MILLIONS)
      • POC Immunoassays
        • TABLE 192: GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 31: GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, 2015-2020 ($ MILLIONS)
      • Cardiac Markers
        • TABLE 193: TYPES OF CARDIAC MARKERS
      • POC Market Penetration
      • Future Outlook
    • BLOOD TRANSFUSION DIAGNOSTIC AND BLOOD SCREENING MARKET
      • TABLE 194: KEY MARKET PLAYERS IN THE BLOOD SCREENING MARKET
    • CONCLUSIONS

CHAPTER 12 - GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS

  • THERAPEUTIC DRUG MARKET
    • TABLE 195: GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 32: GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, 2012-2020 ($ MILLIONS)
    • TABLE 196: GLOBAL MARKET SHARES OF TREATMENTS FOR HEMATOLOGICAL DISORDERS BY TYPE, 2015 AND 2020 (%)
  • KEY MARKET PLAYERS
    • TABLE 197: PATENT EXPIRIES OF MAJOR BLOCKBUSTERS DRUGS
    • TABLE 198: GLOBAL KEY PLAYERS OF HEMATOLOGICAL DISORDERS MARKET BY PRODUCTS AND MARKET SHARE, 2015 (%)
    • TABLE 199: MARKET DRIVERS OF HEMATOLOGICAL DISORDERS
    • TABLE 200: MARKET RESTRAINTS OF HEMATOLOGICAL DISORDERS
  • ANEMIA TREATMENT MARKET
    • TABLE 201: GLOBAL ANEMIA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
    • FIGURE 33: GLOBAL ANEMIA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
    • TABLE 202: TYPES OF ANEMIA
    • Anemia Treatments
      • TABLE 203: COMMON ANEMIA TREATMENTS
      • TABLE 204: ERYTHROPOIETIN STIMULATING AGENTS
    • Aranesp
      • TABLE 205: KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS)
      • FIGURE 34: KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS)
    • Epogen
    • Procrit
    • Costs
    • NeoRecormon
      • TABLE 206: GLOBAL NEORECORMON MARKET, 2010-2015* ($ MILLIONS)
      • FIGURE 35: GLOBAL NEORECORMON MARKET, 2010-2015* ($ MILLIONS)
      • TABLE 207: GLOBAL NEORECORMON MARKET, 2009 ($ MILLIONS)
    • Biosimilars
      • TABLE 208: BIOSIMILARS OF EPOETIN ALFA AND DARBEPOETIN ALFA
    • Medicare and Anemia Drug Usage
    • Market Trends
    • Drug Profiles
      • Promacta (Eltrombopag)
      • Roxadustat
      • Peginesatide
    • Future Strategies
    • Major Players
      • GlaxoSmithKline and Bayer
      • FibroGen
      • Stanford
      • Ligand
      • Pluristem Therapeutics
      • AMAG Pharma
      • Akebia Therapeutics
        • TABLE 209: AKEBIA THERAPEUTICS: ANEMIA DRUG IN DEVELOPMENT-AKB-6548
  • THROMBOSIS TREATMENT MARKET
    • TABLE 210: GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 36: GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, 2012-2020 ($ MILLIONS)
    • TABLE 211: LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET
    • Anticoagulant Market
      • TABLE 212: GLOBAL ANTICOAGULANT DRUG MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 37: GLOBAL ANTICOAGULANT DRUG MARKET, 2012-2020 ($ MILLIONS)
      • Oral Anticoagulants
      • Injectable Anticoagulants
      • Development of New Drugs and Market
    • Antiplatelet Market
      • TABLE 213: GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 38: GLOBAL ANTIPLATELET DRUG MARKET, 2012-2020 ($ MILLIONS)
    • Drug Profiles
      • Plavix
        • Generic Versions of Clopidogrel
        • Plavix: History
        • Plavix Market Trends
          • TABLE 214: SOME COMMON ANTIPLATELET AND ANTICOAGULANT
      • Effient/Efient
    • Competition in the Antiplatelet Market
      • TABLE 215: GLOBAL ANTIPLATELET DRUGS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 216: U.S. SALES OF PLAVIX, 2012 ($ MILLIONS)
    • Drug Profiles
      • Brilinta
      • Edoxaban/Savaysa/Lixiana
        • Semuloparin
      • Lovenox/Enoxaparin
        • Generic Lovenox
          • TABLE 217: GLOBAL ANTITHROMBOTIC AGENTS MARKET, THROUGH 2020 ($ MILLIONS)
        • Lovenox History
      • New Drugs
        • Kengrexal
        • Zontivity
      • Market Dynamics
    • Anticoagulant Market
      • Drug Profiles
        • Eliquis
        • Xarelto
          • TABLE 218: XARELTO: APPROVALS IN VENOUS ARTERIAL THROMBOEMBOLIC INDICATIONS
        • Pradaxa
        • Arixtra
        • Activase
          • TABLE 219: GLOBAL ACTIVASE MARKET, THROUGH 2020 ($ MILLIONS)
        • Angiomax
      • Market Trends for Anticoagulants
        • Warfarin
  • PLATELET AGGREGATION INHIBITORS AND MARKET IMPACT
    • TABLE 220: KEY PLATELET AGGREGATION INHIBITOR DRUG MARKET, 2012 AND 2015 ($ MILLIONS)
    • TABLE 221: PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS
    • Cangrelor
    • Heparin Market and Market Dynamics
      • TABLE 222: KEY PLAYERS IN THE GLOBAL HEPARIN MARKET
      • TABLE 223: THROMBOSIS MARKET: PIPELINE DRUGS
      • TABLE 224: PLATELET INHIBITOR: PIPELINE DRUGS
  • NEUTROPENIA TREATMENT MARKET
    • TABLE 225: GLOBAL NEUTROPENIA DRUG MARKET, THROUGH 2020 ($ MILLIONS)
    • FIGURE 39: GLOBAL NEUTROPENIA DRUG MARKET, 2012-2020 ($ MILLIONS)
    • TABLE 226: COMPANY MARKET SHARES OF KEY NEUTROPENIA DRUGS, 2015 (%)
    • Neulasta (Pegfilgrastim) and Neupogen (Filgrastim)
      • TABLE 227: GROWTH FACTORS FOR TREATING NEUTROPENIA
      • TABLE 228: GLOBAL NEULASTA/NEUPOGEN MARKET, 2012 AND 2015 ($ MILLIONS)
      • TABLE 229: GLOBAL SARGRAMOSTIM MARKET, 2010 ($ MILLIONS)
    • Filgrastim Biosimilars
      • TABLE 230: COMPANIES WITH SHORT-ACTING FILGRASTIMS IN PHASE III CLINICAL DEVELOPMENT IN EUROPE
      • TABLE 231: FILGRASTIM PRODUCTS
    • Teva Pharmaceutical
    • Competition in the Neutropenia Market
  • HEMOPHILIA MARKET
    • TABLE 232: GLOBAL HEMOPHILIA THERAPEUTICS MARKET, THROUGH 2020 ($ MILLIONS)
    • FIGURE 40: GLOBAL HEMOPHILIA THERAPEUTICS MARKET, 2012-2020 ($ MILLIONS)
    • New Products
      • TABLE 233: GLOBAL KEY HEMOPHILIA PLAYERS
    • Gene Therapy
    • Drugs for the Hemophilia Market
      • TABLE 234: KEY HEMOPHILIA DRUGS
      • TABLE 235: GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 ($ MILLIONS)
      • FIGURE 41: GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 ($ MILLIONS)
    • Market Barriers
    • Drug Pipeline
      • TABLE 236: OTHER COAGULATION PRODUCTS
    • Bayer
      • TABLE 237: GENE THERAPY PROGRAMS IN HEMOPHILIA
    • Other Molecules
      • TABLE 238: FDA APPROVED DRUGS FOR HEMATOLOGY, AUG. 2013-MARCH 2016
      • Advate
      • Biogen Idec
    • Blood Disorders Pipeline
      • TABLE 239: APPROVALS BY HEALTH CANADA, MARCH 2014-JAN. 2016
  • CONCLUSIONS

CHAPTER 13 - HEMATOLOGICAL CANCER THERAPIES MARKET

  • OVERVIEW
    • TABLE 240: CANCER IN THE UNITED STATES
    • HEMATOLOGICAL CANCERS DRUG MARKET
    • CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES
      • CHRONIC MYELOID DISORDERS
    • GLOBAL CYTOTOXIC THERAPIES MARKET
      • TABLE 241: CYTOTOXIC THERAPIES MARKET INDICATIONS
      • TABLE 242: LIST OF MEDICATIONS
      • TABLE 243: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
      • FIGURE 42: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
    • U.S. CYTOTHERAPEUTICS MARKET
      • TABLE 244: U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
      • FIGURE 43: U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • EUROPEAN CYTOTHERAPEUTICS MARKET
      • TABLE 245: EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
      • FIGURE 44: EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • JAPANESE CYTOTHERAPEUTICS MARKET
      • TABLE 246: JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
      • FIGURE 45: JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • LEUKEMIA MARKET AND CHALLENGES
      • TABLE 247: MAJOR LEUKEMIA PLAYERS
    • IS THERE AN UNMET NEED?
      • TABLE 248: RECENT LEUKEMIA INCIDENCE PERCENTAGE BY CATEGORY (%)
      • TABLE 249: GLOBAL LEUKEMIA MARKET, BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 46: GLOBAL LEUKEMIA MARKET, BY TYPE, 2012-2020 ($ MILLIONS)
    • GLOBAL LEUKEMIA MARKET
      • TABLE 250: LEUKEMIA MARKET SHARE FORECAST, BY COUNTRY, 2011 (%)
      • U.S. Leukemia Market
        • TABLE 251: U.S. LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 47: U.S. LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
      • European Leukemia Market
        • TABLE 252: EUROPEAN LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 48: EUROPEAN LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
      • Japanese Leukemia Market
        • TABLE 253: JAPAN'S LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 49: JAPAN'S LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
        • TABLE 254: GLOBAL LEUKEMIA MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 50: GLOBAL LEUKEMIA MARKET BY REGION, 2012-2020 ($ MILLIONS)
    • CHRONIC MYELOGENOUS LEUKEMIA MARKET
      • TABLE 255: GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 51: GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • MARKET TRENDS AND THERAPEUTIC DRUGS
      • TABLE 256: DRUG CLASSES' FOR LEUKEMIA DRUG DEVELOPMENT
      • TABLE 257: KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 ($ MILLIONS)
      • FIGURE 52: KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 ($ MILLIONS)
      • Market Trends
      • Therapeutic Drugs
        • Gleevec
          • TABLE 258: KEY CML MEDICINES AND COST
          • TABLE 259: GLEEVAC FDA APPROVALS, 2002-2012
        • Tasigna
        • Sprycel
        • Combination Treatment
      • New Drugs for CML
      • Drug Profiles
        • Bosulif
        • Synribo
        • Bafetinib
        • Rebastinib/DCC-2036
        • Danusertib
          • TABLE 260: RECENT PIPELINE DRUGS FOR LEUKEMIA
        • Ponatinib
    • ACUTE LYMPHOCYTIC LEUKEMIA MARKET
      • TABLE 261: GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 53: GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, 2012-2020 ($ MILLIONS)
      • TABLE 262: MAJOR ACUTE LYMPHOCYTIC LEUKEMIA PLAYERS IN THE MARKET
    • ACUTE LYMPHOCYTIC LEUKEMIA AND CHILDREN
      • THERAPEUTICS
        • TABLE 263: DRUGS FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL) TREATMENT
        • Clolar
        • Oncaspar
        • Nelarabine
        • Marqibo
          • TABLE 264: APPROVED DRUGS FOR ALL
        • Graspa
      • ACUTE MYELOID LEUKEMIA (AML) MARKET
        • TABLE 265: GLOBAL ACUTE MYELOID LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 54: GLOBAL ACUTE MYELOID LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • THERAPEUTIC DRUGS
      • Elacytarabine
      • Quizartinib
    • KEY COMPANIES
      • TABLE 266: KEY COMPANIES IN THE AML MARKET
    • NEW DEVELOPMENTS
      • Astex Pharmaceuticals
    • ACUTE MYELOID LEUKEMIA AND CHILDREN
      • Treatment Costs
    • CHRONIC LYMPHOCYTIC LEUKEMIA MARKET
      • TABLE 267: GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 55: CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • THERAPEUTIC DRUGS
      • Arzerra
        • TABLE 268: GLOBAL ARZERRA MARKET, 2010-2015 ($ MILLIONS)
      • Fludara
      • Campath
      • Treanda
        • TABLE 269: GLOBAL TREANDA MARKET, 2014-2017 ($ MILLIONS)
    • PIPELINE
      • Venetoclax
      • NOX-A12 anti-CXCL12/SDF-1/Spiegelmer
        • TABLE 270: NOX-A12: HOW DOES IT WORK?
      • Imbruvica/Ibrutinib
      • Idelalisib/GS-1101
        • TABLE 271: GILEAD: HEMATOLOGY AND ONCOLOGY PIPELINE
    • NEW DEVELOPMENTS
      • Blinatumomab
    • NEW DRUGS IN DEVELOPMENT
      • Combining the Targeted Drugs with Other Treatments
    • NEW DRUGS FOR CML
    • CANCER VACCINES
  • LYMPHOMA DRUG MARKET
    • MARKET TRENDS
      • TABLE 272: GENERIC DRUGS USED IN COMBINATION TO TREAT HODGKIN LYMPHOMA
      • TABLE 273: DRUGS USED IN COMBINATION TO TREAT NON-HODGKIN LYMPHOMA
    • CHEMOTHERAPY
    • BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTS
    • TARGETED THERAPIES
      • Antibiotics
      • Monoclonal Antibodies
      • Lymphoma Vaccines
      • Idelalisib
    • NON-HODGKIN LYMPHOMA DRUG MARKET
      • TABLE 274: GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 56: GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, 2012-2020 ($ MILLIONS)
      • Rituximab
        • TABLE 275: GLOBAL RITUXIMAB MARKET, 2010-2015 ($ MILLIONS)
      • Rituxan Biosimilars Development and Key Companies
        • TABLE 276: RITUXAN: BIOSIMILARS IN DEVELOPMENT
      • New Drugs
        • Revlimid
          • TABLE 277: GLOBAL REVLIMID MARKET, 2011-2015 ($ MILLIONS)
    • HODGKIN LYMPHOMA TREATMENT MARKET
      • TABLE 278: GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 57: GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
      • Market Dynamics and Pipeline
        • Adcetris/Brentuximab Vedotin
        • Farydak/Panobinostat
    • MULTIPLE MYELOMA TREATMENT MARKET
      • TABLE 279: GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 58: GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
      • TABLE 280: DRUGS FOR THE MYELOMA MARKET
    • THERAPEUTIC DRUGS
      • Kyprolis
      • Revlimid
      • Velcade
      • Pomalidomide
    • PIPELINE DRUG CANDIDATES
      • TABLE 281: PIPELINE DRUGS FOR MYELOMA IN DEVELOPMENT
      • Obatoclax
      • Perifosine
      • Panobinostat (Faridak)
      • Aplidin
      • Treanda
        • TABLE 282: TREANDA CLINICAL TRIALS IN RELAPSED AND/OR REFRACTORY MYELOMA
    • MYELODYSPLASTIC SYNDROME MARKET
      • TABLE 283: GLOBAL MYELODYSPLASTIC SYNDROME MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 59: GLOBAL MYELODYSPLASTIC SYNDROME MARKET, 2012-2020 ($ MILLIONS)
    • MDS THERAPIES
      • TABLE 284: APPROVED DRUGS FOR THE TREATMENT OF MDS
      • Decitabine
      • Vidaza
    • PIPELINE
      • TABLE 285: DRUGS IN CLINICAL DEVELOPMENT
    • MYELOPROLIFERATIVE DISORDERS
      • TABLE 286: GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 60: GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, 2012-2020 ($ MILLIONS)
    • MARKET TRENDS
      • TABLE 287: JAK2 INHIBITORS IN DEVELOPMENT
    • THERAPEUTIC DRUGS
      • Jakafi/Ruxolitinib
        • TABLE 288: GLOBAL JAKAFI/RUXOLITINIB MARKET, THROUGH 2020 ($ MILLIONS)
      • TG101348
      • AZD1480
      • R723
      • XL019
      • CYT387
      • SB1518
  • MARKET FOR ESSENTIAL THROMBOCYTOSIS (ET)
    • MYELOFIBROSIS MARKET
      • TABLE 289: GLOBAL MYELOFIBROSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 61: GLOBAL MYELOFIBROSIS MARKET, 2012-2020 ($ MILLIONS)
  • TREATMENT OPTIONS FOR MYELOFIBROSIS
    • POLYCYTHEMIA VERA (PV) THERAPEUTICS MARKET
      • TABLE 290: GLOBAL POLYCYTHEMIA VERA MARKET, THROUGH 2020 ($ MILLIONS)
      • FIGURE 62: GLOBAL POLYCYTHEMIA VERA MARKET, 2012-2020 ($ MILLIONS)
  • TREATMENT EXPENSE

CHAPTER 14 - PATENT LANDSCAPE AND CURRENT DEVELOPMENTS

  • TABLE 291: MAJOR BLOOD DISORDER DRUG PATENT EXPIRIES, 2009-2015
  • TABLE 292: KEY BLOOD DISORDER DRUGS: PATENT EXPIRY
  • TABLE 293: DRUGS LOSING PATENT PROTECTION BY 2015, GLOBAL SALES 2010 ($ MILLIONS)
  • HEMATOLOGICAL CANCER DRUG PATENT EXPIRIES
    • TABLE 294: BIOLOGIC DRUG PATENT EXPIRIES
  • NEW APPROVALS
    • TABLE 295: NEW DRUG APPROVALS FOR BLOOD DISORDERS, 2012
  • NEW HEMATOLOGICAL CANCER DRUGS
    • TABLE 296: NEW DRUG APPROVALS FOR HEMATOLOGICAL CANCERS, 2012
    • NEWS AND DEVELOPMENTS
      • Type 2 Diabetes Linked to Increased Blood Cancer Risk
    • NOVARTIS AND PATENT ISSUES
    • DRUGS IN DEVELOPMENT
      • Ariad Pharmaceuticals
      • Pharmacyclics
      • AiCuris
      • Cell Therapeutics
      • Biogen Idec/Swedish Orphan Biovitrum
      • Inspiration Biopharmaceuticals
      • Novartis
      • Merck
      • The Medicines Co.
      • Isis Pharmaceuticals
      • CytoPharm and Amarillo Biosciences
      • SuppreMol
      • MorphoSys and Xencor
      • ARIAD Pharmaceuticals
    • OTHER DEVELOPMENTS
      • Universal Cancer Blood Test
      • Boehringer Ingelheim
      • Janssen Biotech
      • Mergers
      • Blood Disorders News
      • AMAG Pharmaceuticals
      • Affymax vs. Amgen
    • ACQUISITIONS
      • Gilead Sciences

CHAPTER 15 - SELECTED COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ABON PHARMACEUTICALS
  • AMBIT BIOSCIENCES
  • AMGEN
  • AMPHASTAR PHARMACEUTICALS
  • ARIAD PHARMACEUTICALS
  • ASTELLAS PHARMA US
  • ASTEX PHARMACEUTICALS
  • ASTRAZENECA
  • BAXALTA INC.
  • BAXTER HEALTHCARE CORP.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CELGENE CORP.
  • CHUGAI PHARMACEUTICAL
  • C.R. BARD
  • CZ BIOMED CORP.
  • DAIICHI SANKYO CO. LTD.
  • DECIPHERA PHARMACEUTICALS
  • DIAGNOCURE
  • EISAI INC.
  • ELI LILLY AND CO.
  • ENZON PHARMACEUTICALS
  • ERYTECH PHARMA SA
  • EXELIXIS
  • GE HEALTHCARE
  • GENENTECH INC.
  • GENMAB INC.
  • GILEAD SCIENCES
  • GLAXOSMITHKLINE
  • HOLOGIC
  • HORIBA LTD.
  • JOHNSON & JOHNSON
  • THE MEDICINES CO.
  • MEDKOO BIOSCIENCES
  • MOMENTA PHARMACEUTICALS
  • NOXXON PHARMA AG
  • PORTOLA PHARMACEUTICALS INC.
  • OPKO HEALTH
  • OTSUKA PHARMACEUTICAL
  • PFIZER
  • PHARMACYCLICS
  • ROCHE DIAGNOSTICS
  • SANDOZ INTERNATIONAL GMBH
  • SANOFI
  • SIEMENS AG
  • SPECTRUM PHARMACEUTICALS
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • WATSON PHARMACEUTICALS INC.
  • YM BIOSCIENCES INC.

CHAPTER 16 - BIBLIOGRAPHY

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: KEY BLOOD DISORDERS
    • TABLE 2: MALIGNANT BLOOD DISORDERS
    • TABLE 3: NONMALIGNANT BLOOD DISORDERS
    • TABLE 4: TYPE OF BLOOD CELLS AND FUNCTIONS
    • TABLE 5: COMPONENTS OF BLOOD
    • TABLE 6: THREE MAJOR TYPES OF ANEMIA
    • TABLE 7: CAUSES OF ANEMIA
    • TABLE 8: SYMPTOMS OF ANEMIA
    • TABLE 9: ANEMIA: TYPES, CAUSES AND TREATMENT
    • TABLE 10: DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY BY CLASS
    • TABLE 11: DRUGS THAT CAN CAUSE FOLATE DEFICIENCY
    • TABLE 12: SICKLE CELL ANEMIA: KEY FACTS
    • TABLE 13: LAB TESTS FOR ANEMIA
    • TABLE 14: HEMOSTASIS: THREE MAJOR STEPS
    • TABLE 15: DRUGS THAT AFFECT THE ACTIVITY OF PLATELETS
    • TABLE 16: ANTICOAGULANTS THAT ACT ON THROMBIN
    • TABLE 17: BLEEDING DISORDERS
    • TABLE 18: SYMPTOMS OF BLEEDING DISORDERS
    • TABLE 19: SIGNS AND TESTS FOR BLEEDING DISORDERS
    • TABLE 20: KEY CHARACTERISTICS OF HEMOPHILIA
    • TABLE 21: FVIII INHIBITORS
    • TABLE 22: MEDICATIONS FOR TREATING HEMOPHILIA
    • TABLE 23: FACTOR VIII PRODUCTS
    • TABLE 24: ANTIFIBRINOLYTICS BY DRUG
    • TABLE 25: ANTIHEMOPHILIC AGENTS BY CLASS
    • TABLE 26: FORMATION OF THROMBUS
    • TABLE 27: CAUSES OF NEUTROPENIA
    • TABLE 28: WHITE BLOOD CELL DISORDERS
    • TABLE 29: CAUSES OF SECONDARY THROMBOCYTOSIS
    • TABLE 30: DIAGNOSTIC TESTS FOR THROMBOCYTHEMIA
    • TABLE 31: MEDICINES FOR THROMBOCYTHEMIA
    • TABLE 32: CAUSES OF THROMBOCYTOPENIA
    • TABLE 33: SIGNS OF EXTERNAL BLEEDING
    • TABLE 34: COMMON DRUGS TO TREAT EOSINOPHILIA
    • TABLE 35: HEMATOLOGICAL CANCERS (BLOOD CANCERS)
    • TABLE 36: RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE U.S., 2016 (NUMBER/%)
    • TABLE 37: TYPES OF HEMATOLOGICAL CANCERS
    • TABLE 38: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2014-2016
    • TABLE 39: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2012
    • TABLE 40: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2011
    • TABLE 41: FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 1996-2010
    • TABLE 42: TYPES OF LEUKEMIA
    • TABLE 43: TYPES OF LEUKEMIA AND KEY FEATURES
    • TABLE 44: DIAGNOSTIC EXAMS FOR LEUKEMIA
    • TABLE 45: ADDITIONAL TESTS
    • TABLE 46: PCR TESTS
    • TABLE 47: NON-LABORATORY TESTS
    • TABLE 48: COMMON TREATMENTS USED TO FIGHT LEUKEMIA
    • TABLE 49: NEWER CLASSES OF DRUGS
    • TABLE 50: ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT
    • TABLE 51: DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
    • TABLE 52: DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA
    • TABLE 53: DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA
    • TABLE 54: DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA
    • TABLE 55: T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN
    • TABLE 56: FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS
    • TABLE 57: CHEMOTHERAPY DRUGS FOR CML
    • TABLE 58: CHEMOTHERAPY DRUGS FOR CLL
    • TABLE 59: TARGETED THERAPY DRUGS
    • TABLE 60: ADVANTAGES OF RADIOIMMUNOTHERAPY
    • TABLE 61: COMMON RADIATION TREATMENTS: LEUKEMIA
    • TABLE 62: PAIN MEDICATIONS
    • TABLE 63: EMERGING THERAPIES FOR LEUKEMIA
    • TABLE 64: CAUSES OF LYMPHOMA
    • TABLE 65: LYMPHOMA TYPES
    • TABLE 66: STAGING FOR HL AND NHL TUMORS
    • TABLE 67: MATURE B-CELL NEOPLASMS
    • TABLE 68: MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS
    • TABLE 69: HODGKIN LYMPHOMA
    • TABLE 70: IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS
    • TABLE 71: SYMPTOMS OF NON-HODGKIN LYMPHOMA
    • TABLE 72: FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS: NON HODGKIN LYMPHOMA, 2006-2012 (%)
    • TABLE 73: IMAGING TESTS FOR LYMPHOMA
    • TABLE 74: THE INTERNATIONAL PROGNOSTIC INDEX FOR HL
    • TABLE 75: THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL
    • TABLE 76: PROMISING THERAPIES FOR TREATING LYMPHOMA
    • TABLE 77: PROGNOSTIC INDICATORS FOR MYELOMA
    • TABLE 78: OTHER BONE MARROW TESTS
    • TABLE 79: MYELOMA: STAGING CRITERIA
    • TABLE 80: MYELOMA'S RESPONSE TO TREATMENT
    • TABLE 81: SUPPORTIVE CARE FOR MYELOMA
    • TABLE 82: DRUGS FOR MULTIPLE MYELOMA
    • TABLE 83: NEW AND EMERGING THERAPIES FOR MYELOMA
    • TABLE 84: CHARACTERISTICS OF MDS
    • TABLE 85: CAUSES OF MDS
    • TABLE 86: MDS OR AML: THREE CATEGORIES
    • TABLE 87: MYELODYSPLASTIC SYNDROMES: KEY FACTS
    • TABLE 88: FAB CLASSIFICATION OF MDS
    • TABLE 89: THE 2008 WHO CLASSIFICATION OF MDS
    • TABLE 90: INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS AND PROGNOS (YEARS)
    • TABLE 91: CHANGES IN CELLS DUE TO MDS
    • TABLE 92: CHRONIC MYELOPROLIFERATIVE DISORDERS
    • TABLE 93: CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE 2008 WHO CLASSIFICATION SCHEME
    • TABLE 94: MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS
    • TABLE 95: DIAGNOSTIC TESTS
    • TABLE 96: SYMPTOMS OF POLYCYTHEMIA VERA
    • TABLE 97: BLOOD TESTS FOR POLYCYTHEMIA VERA
    • TABLE 98: TREATMENT FOR POLYCYTHEMIA VERA
    • TABLE 99: CAUSATIVE FACTORS FOR MYELOFIBROSIS
    • TABLE 100: POTENTIAL COMPLICATIONS FROM MYELOFIBROSIS
    • TABLE 101: WHO DIAGNOSTIC CRITERIA FOR PMF
    • TABLE 102: RISK FACTORS
    • TABLE 103: IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS
    • TABLE 104: PROGNOSIS FACTORS
    • TABLE 105: TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS
    • TABLE 106: SOMATIC MUTATIONS
    • TABLE 107: CAUSES OF THROMBOCYTOSIS
    • TABLE 108: SYMPTOMS OF ESSENTIAL THROMBOCYTOSIS
    • TABLE 109: ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA
    • TABLE 110: TREATMENT OF ET
    • TABLE 111: TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
    • TABLE 112: SYMPTOMS OF CHRONIC EOSINOPHILIC LEUKEMIA
    • TABLE 113: TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA
    • TABLE 114: CURRENT DRUGS
    • TABLE 115: CANCER KEY FACTS
    • TABLE 116: INCREASE IN CANCER BURDEN: FACTORS
    • TABLE 117: GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO./%)
    • TABLE 118: GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO.)
    • TABLE 119: GLOBAL INCIDENCE OF BLOOD CANCERS IN MEN, 2012 (NO./%)
    • TABLE 120: GLOBAL INCIDENCE OF BLOOD CANCERS IN WOMEN, 2012 (NO./%)
    • TABLE 121: TOP 10 COUNTRIES' CANCER INCIDENCE RATES (PER 100,000 POPULATION)
    • TABLE 122: ESTIMATED INCIDENCE OF BLOOD CANCERS IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)
    • TABLE 123: ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)
    • TABLE 124: ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
    • TABLE 125: GLOBAL INCIDENCE OF LEUKEMIA, 2012 (NUMBER/%)
    • TABLE 126: U.S. LEUKEMIA INCIDENCE STATISTICS, 2012
    • TABLE 127: ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)
    • TABLE 128: ESTIMATED NEW CASES OF LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2016
    • TABLE 129: ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)
    • TABLE 130: PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)
    • TABLE 131: TYPES OF LEUKEMIA IN ADULTS IN THE U.S. AND AGE GROUP
    • TABLE 132: ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)
    • TABLE 133: AGE-ADJUSTED INCIDENCE RATES OF LEUKEMIA IN THE U.S. BY RACE, SEER 18, 2009-2013 (PER 100,000 POPULATION)
    • TABLE 134: FIVE-YEAR RELATIVE SURVIVAL RATES IN THE U.S. FOR LEUKEMIA, 2005-2011 (%)
    • TABLE 135: ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO).
    • TABLE 136: NEW CASES OF LEUKEMIA IN THE U.K., 2013 (NO.)
    • TABLE 137: GLOBAL ESTIMATES OF LEUKEMIA DEATHS/MORTALITY RATES, 2012
    • TABLE 138: GLOBAL ESTIMATED INCIDENCE RATES OF NON-HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012
    • TABLE 139: GLOBAL ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES BY ALL AGES AND BOTH SEXES, 2012
    • TABLE 140: GLOBAL ESTIMATED INCIDENCE OF HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012
    • TABLE 141: ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)
    • TABLE 142: ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)
    • TABLE 143: ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)
    • TABLE 144: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
    • TABLE 145: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)
    • TABLE 146: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)
    • TABLE 147: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)
    • TABLE 148: ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)
    • TABLE 149: U.S. AGE-SPECIFIC NHL INCIDENCE RATES BY GENDER (ESTIMATED RATES PER 100,000 POPULATION)
    • TABLE 150: U.S. LYMPHOMA INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)
    • TABLE 151: U.S. LYMPHOMA MORTALITY RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)
    • TABLE 152: STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES, BOTH SEXES BY STAGE AT DIAGNOSIS, 2002-2008 (%)
    • TABLE 153: NEW CASES OF NON-HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)
    • TABLE 154: NON-HODGKIN LYMPHOMA DEATHS IN THE U.K. BY SEX, 2012 (NO.)
    • TABLE 155: ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)
    • TABLE 156: ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)
    • TABLE 157: ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)
    • TABLE 158: ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)
    • TABLE 159: ESTIMATED INCIDENCE OF MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)
    • TABLE 160: DEATHS FROM MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)
    • TABLE 161: ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)
    • TABLE 162: ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)
    • TABLE 163: AGE-ADJUSTED INCIDENCE RATES OF MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)
    • TABLE 164: AGE-ADJUSTED DEATH RATES FROM MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)
    • TABLE 165: DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL FOR ALL AGES AND BOTH SEXES IN THE U.S. BY STAGE AT DIAGNOSIS, 2002-2008 (%)
    • TABLE 166: NEW CASES OF MYELOMA IN THE U.K., 2013 (NO.)
    • TABLE 167: MYELOMA DEATHS IN THE U.K., 2012 (NO.)
    • TABLE 168: ESTIMATED NEW CASES OF MDS IN THE U.S., 2012 (NO.)
    • TABLE 169: KEY FACTORS DRIVING THE GROWTH OF THE HEMATOLOGICAL DISORDERS MARKET
    • TABLE 170: GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 171: KEY HEMATOLOGY PRODUCTS
    • TABLE 172: GLOBAL MAJOR COMPANIES IN THE HEMATOLOGY MARKET
    • TABLE 173: KEY PLAYERS IN FLOW CYTOMETRY
    • TABLE 174: GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 175: MAJOR FLOW CYTOMETRY APPLICATIONS
    • TABLE 176: CELL ANALYZERS
    • TABLE 177: HEMATOLOGY TESTS
    • TABLE 178: COMPLETE BLOOD COUNT: COMPONENTS MEASURED
    • TABLE 179: TESTS INCLUDED IN A CHEMISTRY SCREEN
    • TABLE 180: CHEMISTRY SCREEN
    • TABLE 181: URINE TESTS AND APPLICATIONS
    • TABLE 182: GLOBAL IVD PRODUCTS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 183: U.S. IVD MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 184: GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, THROUGH 2020 ($ MILLIONS)
    • TABLE 185: GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, THROUGH 2020 ($ MILLIONS)
    • TABLE 186: KEY PLAYERS IN THE IMMUNOASSAYS MARKET
    • TABLE 187: GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 188: MAJOR PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
    • TABLE 189: GLOBAL POINT-OF-CARE TESTING MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 190: POC TESTING KITS
    • TABLE 191: GLOBAL MARKET FOR POC TESTS, THROUGH 2020 ($ MILLIONS)
    • TABLE 192: GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 193: TYPES OF CARDIAC MARKERS
    • TABLE 194: KEY MARKET PLAYERS IN THE BLOOD SCREENING MARKET
    • TABLE 195: GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 196: GLOBAL MARKET SHARES OF TREATMENTS FOR HEMATOLOGICAL DISORDERS BY TYPE, 2015 AND 2020 (%)
    • TABLE 197: PATENT EXPIRIES OF MAJOR BLOCKBUSTERS DRUGS
    • TABLE 198: GLOBAL KEY PLAYERS OF HEMATOLOGICAL DISORDERS MARKET BY PRODUCTS AND MARKET SHARE, 2015 (%)
    • TABLE 199: MARKET DRIVERS OF HEMATOLOGICAL DISORDERS
    • TABLE 200: MARKET RESTRAINTS OF HEMATOLOGICAL DISORDERS
    • TABLE 201: GLOBAL ANEMIA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 202: TYPES OF ANEMIA
    • TABLE 203: COMMON ANEMIA TREATMENTS
    • TABLE 204: ERYTHROPOIETIN STIMULATING AGENTS
    • TABLE 205: KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS)
    • TABLE 206: GLOBAL NEORECORMON MARKET, 2010-2015* ($ MILLIONS)
    • TABLE 207: GLOBAL NEORECORMON MARKET, 2009 ($ MILLIONS)
    • TABLE 208: BIOSIMILARS OF EPOETIN ALFA AND DARBEPOETIN ALFA
    • TABLE 209: AKEBIA THERAPEUTICS: ANEMIA DRUG IN DEVELOPMENT-AKB-6548
    • TABLE 210: GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 211: LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET
    • TABLE 212: GLOBAL ANTICOAGULANT DRUG MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 213: GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 214: SOME COMMON ANTIPLATELET AND ANTICOAGULANT
    • TABLE 215: GLOBAL ANTIPLATELET DRUGS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 216: U.S. SALES OF PLAVIX, 2012 ($ MILLIONS)
    • TABLE 217: GLOBAL ANTITHROMBOTIC AGENTS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 218: XARELTO: APPROVALS IN VENOUS ARTERIAL THROMBOEMBOLIC INDICATIONS
    • TABLE 219: GLOBAL ACTIVASE MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 220: KEY PLATELET AGGREGATION INHIBITOR DRUG MARKET, 2012 AND 2015 ($ MILLIONS)
    • TABLE 221: PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS
    • TABLE 222: KEY PLAYERS IN THE GLOBAL HEPARIN MARKET
    • TABLE 223: THROMBOSIS MARKET: PIPELINE DRUGS
    • TABLE 224: PLATELET INHIBITOR: PIPELINE DRUGS
    • TABLE 225: GLOBAL NEUTROPENIA DRUG MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 226: COMPANY MARKET SHARES OF KEY NEUTROPENIA DRUGS, 2015 (%)
    • TABLE 227: GROWTH FACTORS FOR TREATING NEUTROPENIA
    • TABLE 228: GLOBAL NEULASTA/NEUPOGEN MARKET, 2012 AND 2015 ($ MILLIONS)
    • TABLE 229: GLOBAL SARGRAMOSTIM MARKET, 2010 ($ MILLIONS)
    • TABLE 230: COMPANIES WITH SHORT-ACTING FILGRASTIMS IN PHASE III CLINICAL DEVELOPMENT IN EUROPE
    • TABLE 231: FILGRASTIM PRODUCTS
    • TABLE 232: GLOBAL HEMOPHILIA THERAPEUTICS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 233: GLOBAL KEY HEMOPHILIA PLAYERS
    • TABLE 234: KEY HEMOPHILIA DRUGS
    • TABLE 235: GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 ($ MILLIONS)
    • TABLE 236: OTHER COAGULATION PRODUCTS
    • TABLE 237: GENE THERAPY PROGRAMS IN HEMOPHILIA
    • TABLE 238: FDA APPROVED DRUGS FOR HEMATOLOGY, AUG. 2013-MARCH 2016
    • TABLE 239: APPROVALS BY HEALTH CANADA, MARCH 2014-JAN. 2016
    • TABLE 240: CANCER IN THE UNITED STATES
    • TABLE 241: CYTOTOXIC THERAPIES MARKET INDICATIONS
    • TABLE 242: LIST OF MEDICATIONS
    • TABLE 243: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
    • TABLE 244: U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • TABLE 245: EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • TABLE 246: JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • TABLE 247: MAJOR LEUKEMIA PLAYERS
    • TABLE 248: RECENT LEUKEMIA INCIDENCE PERCENTAGE BY CATEGORY (%)
    • TABLE 249: GLOBAL LEUKEMIA MARKET, BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 250: LEUKEMIA MARKET SHARE FORECAST, BY COUNTRY, 2011 (%)
    • TABLE 251: U.S. LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 252: EUROPEAN LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 253: JAPAN'S LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 254: GLOBAL LEUKEMIA MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 255: GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 256: DRUG CLASSES' FOR LEUKEMIA DRUG DEVELOPMENT
    • TABLE 257: KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 ($ MILLIONS)
    • TABLE 258: KEY CML MEDICINES AND COST
    • TABLE 259: GLEEVAC FDA APPROVALS, 2002-2012
    • TABLE 260: RECENT PIPELINE DRUGS FOR LEUKEMIA
    • TABLE 261: GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 262: MAJOR ACUTE LYMPHOCYTIC LEUKEMIA PLAYERS IN THE MARKET
    • TABLE 263: DRUGS FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL) TREATMENT
    • TABLE 264: APPROVED DRUGS FOR ALL
    • TABLE 265: GLOBAL ACUTE MYELOID LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 266: KEY COMPANIES IN THE AML MARKET
    • TABLE 267: GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 268: GLOBAL ARZERRA MARKET, 2010-2015 ($ MILLIONS)
    • TABLE 269: GLOBAL TREANDA MARKET, 2014-2017 ($ MILLIONS)
    • TABLE 270: NOX-A12: HOW DOES IT WORK?
    • TABLE 271: GILEAD: HEMATOLOGY AND ONCOLOGY PIPELINE
    • TABLE 272: GENERIC DRUGS USED IN COMBINATION TO TREAT HODGKIN LYMPHOMA
    • TABLE 273: DRUGS USED IN COMBINATION TO TREAT NON-HODGKIN LYMPHOMA
    • TABLE 274: GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 275: GLOBAL RITUXIMAB MARKET, 2010-2015 ($ MILLIONS)
    • TABLE 276: RITUXAN: BIOSIMILARS IN DEVELOPMENT
    • TABLE 277: GLOBAL REVLIMID MARKET, 2011-2015 ($ MILLIONS)
    • TABLE 278: GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 279: GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 280: DRUGS FOR THE MYELOMA MARKET
    • TABLE 281: PIPELINE DRUGS FOR MYELOMA IN DEVELOPMENT
    • TABLE 282: TREANDA CLINICAL TRIALS IN RELAPSED AND/OR REFRACTORY MYELOMA
    • TABLE 283: GLOBAL MYELODYSPLASTIC SYNDROME MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 284: APPROVED DRUGS FOR THE TREATMENT OF MDS
    • TABLE 285: DRUGS IN CLINICAL DEVELOPMENT
    • TABLE 286: GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 287: JAK2 INHIBITORS IN DEVELOPMENT
    • TABLE 288: GLOBAL JAKAFI/RUXOLITINIB MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 289: GLOBAL MYELOFIBROSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 290: GLOBAL POLYCYTHEMIA VERA MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 291: MAJOR BLOOD DISORDER DRUG PATENT EXPIRIES, 2009-2015
    • TABLE 292: KEY BLOOD DISORDER DRUGS: PATENT EXPIRY
    • TABLE 293: DRUGS LOSING PATENT PROTECTION BY 2015, GLOBAL SALES 2010 ($ MILLIONS)
    • TABLE 294: BIOLOGIC DRUG PATENT EXPIRIES
    • TABLE 295: NEW DRUG APPROVALS FOR BLOOD DISORDERS, 2012
    • TABLE 296: NEW DRUG APPROVALS FOR HEMATOLOGICAL CANCERS, 2012

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, 2012-2020 ($ MILLIONS)
    • FIGURE 1: ESTIMATED INCIDENCE OF BLOOD CANCERS, IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)
    • FIGURE 2: ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)
    • FIGURE 3: ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
    • FIGURE 4: ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)
    • FIGURE 5: ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)
    • FIGURE 6: PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)
    • FIGURE 7: ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)
    • FIGURE 8: ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO).
    • FIGURE 9: ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000 POPULATION)
    • FIGURE 10: ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES PER 100,000)
    • FIGURE 11: ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED RATES PER 100,000 POPULATION)
    • FIGURE 12: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
    • FIGURE 13: ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)
    • FIGURE 14: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)
    • FIGURE 15: ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)
    • FIGURE 16: ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)
    • FIGURE 17: ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)
    • FIGURE 18: ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)
    • FIGURE 19: ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)
    • FIGURE 20: ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)
    • FIGURE 21: ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)
    • FIGURE 22: GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 23: GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 24: GLOBAL IVD PRODUCTS MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 25: U.S. IVD MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 26: GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, 2012-2020 ($ MILLIONS)
    • FIGURE 27: GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, 2015-2020 ($ MILLIONS)
    • FIGURE 28: GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2015-2020 ($ MILLIONS)
    • FIGURE 29: GLOBAL POINT-OF-CARE TESTING MARKET, 2015-2020 ($ MILLIONS)
    • FIGURE 30: GLOBAL MARKET FOR POC TESTS, 2015-2020 ($ MILLIONS)
    • FIGURE 31: GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, 2015-2020 ($ MILLIONS)
    • FIGURE 32: GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, 2012-2020 ($ MILLIONS)
    • FIGURE 33: GLOBAL ANEMIA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 34: KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS)
    • FIGURE 35: GLOBAL NEORECORMON MARKET, 2010-2015* ($ MILLIONS)
    • FIGURE 36: GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, 2012-2020 ($ MILLIONS)
    • FIGURE 37: GLOBAL ANTICOAGULANT DRUG MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 38: GLOBAL ANTIPLATELET DRUG MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 39: GLOBAL NEUTROPENIA DRUG MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 40: GLOBAL HEMOPHILIA THERAPEUTICS MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 41: GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 ($ MILLIONS)
    • FIGURE 42: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
    • FIGURE 43: U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • FIGURE 44: EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • FIGURE 45: JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
    • FIGURE 46: GLOBAL LEUKEMIA MARKET, BY TYPE, 2012-2020 ($ MILLIONS)
    • FIGURE 47: U.S. LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 48: EUROPEAN LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 49: JAPAN'S LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 50: GLOBAL LEUKEMIA MARKET BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 51: GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 52: KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 ($ MILLIONS)
    • FIGURE 53: GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 54: GLOBAL ACUTE MYELOID LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 55: CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 56: GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 57: GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 58: GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 59: GLOBAL MYELODYSPLASTIC SYNDROME MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 60: GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 61: GLOBAL MYELOFIBROSIS MARKET, 2012-2020 ($ MILLIONS)
    • FIGURE 62: GLOBAL POLYCYTHEMIA VERA MARKET, 2012-2020 ($ MILLIONS)
Back to Top